Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Lockheed Martin Are Up Today

By Lou Whiteman - Updated May 18, 2020 at 5:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stock joined the broader markets in celebrating progress toward a COVID-19 vaccine.

What happened

Shares of Lockheed Martin (LMT 0.15%) rose 4.76% on Monday, as the F-35 manufacturer gained altitude along with the broader market. Investors are feeling optimistic thanks to some promising early results on a potential coronavirus vaccine, lifting hopes that the worst of the COVID-19 pandemic will soon be behind us.

So what

As industrial stocks go, Lockheed Martin has weathered the pandemic pretty well. The stock is down 3% year to date, beating the S&P 500 by about 5 percentage points. Global production and supply chains have been affected somewhat by the pandemic and the resulting shelter-in-place orders, but the company managed to post first-quarter earnings that came in ahead of expectations.

Two Lockheed Martin fighters flying in formation.

Image source: Lockheed Martin.

Still, there's risk to the business from the pandemic, and Lockheed Martin investors have every reason to want to see it resolved as soon as possible. On its first-quarter earnings call, the company warned it expects disruptions to its businesses in the months to come, and tempered full-year expectations as a result.

Defense contractors also need to be concerned that the government response to the pandemic will drain resources that could have otherwise gone to other areas including Pentagon spending, thus deferring future military orders or potentially causing certain programs to be canceled.

Now what

It is worth cautioning that those vaccine trial results that had markets rocketing higher on Monday were from a preliminary, early-stage trial, and we have a long way to go before there is a vaccine ready for distribution. Biotech is full of stories of promising early results that cannot be replicated in future trials, so it is important we don't declare the crisis resolved based on those initial results.

That said, Lockheed Martin looked like a pretty good place to take shelter from the market volatility even without a vaccine. The company has a $144 billion backlog of orders and exposure to areas that the Pentagon has prioritized. There's no reason Lockheed Martin shares shouldn't climb higher in the weeks and quarters to come regardless of how the vaccine trials end up.

Lou Whiteman owns shares of Lockheed Martin. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lockheed Martin Corporation Stock Quote
Lockheed Martin Corporation
$440.03 (0.15%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.